密歇根医院抗菌药物管理与氟喹诺酮类处方关联的多医院队列研究
结果显示管理策略与住院期间氟喹诺酮处方减少相关,但出院后新起始处方反而更多,提示需同时针对住院和出院处方。
要点
- 氟喹诺酮管理策略与住院期间氟喹诺酮使用减少相关。
- 多数氟喹诺酮治疗日发生在出院后。
- 有管理策略的医院出院后新起始氟喹诺酮比例更高。
核心结论
- 针对氟喹诺酮的医院管理干预与住院期间氟喹诺酮处方减少相关,但与出院后处方减少无关。
研究设计与样本
- 医院调查是否使用预先授权和/或前瞻性审核反馈针对氟喹诺酮处方,并控制医院聚类和患者因素后比较总体氟喹诺酮暴露。
主要发现
- 29.2%(14/48)医院报告使用预先授权和/或前瞻性审核反馈针对氟喹诺酮处方。
- 调整后,有管理策略的医院接受氟喹诺酮的患者比例更低(37.1% vs 48.2%;P = .01)。
- 有管理策略的医院每1000患者氟喹诺酮治疗日更少(2282 vs 3096天/1000患者;P = .01),主要由住院处方减少驱动。
- 多数(66.6%)氟喹诺酮治疗日发生在出院后,有管理策略的医院出院后新起始氟喹诺酮比例是无管理策略医院的两倍(15.6% vs 8.4%;P = .003)。
临床怎么用
- 抗菌药物管理项目应同时针对住院和出院时的氟喹诺酮处方,以限制总体暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluoroquinolones increase the risk of Clostridioides difficile infection and antibiotic resistance. Hospitals often use pre-prescription approval or prospective audit and feedback to target fluoroquinolone prescribing. Whether these strategies impact aggregate fluoroquinolone use is unknown. METHODS: This study is a 48-hospital, retrospective cohort of general-care, medical patients hospitalized with pneumonia or positive urine culture between December 2015-September 2017. Hospitals were surveyed on their use of pre-prescription approval and/or prospective audit and feedback to target fluoroquinolone prescribing during hospitalization (fluoroquinolone stewardship). After controlling for hospital clustering and patient factors, aggregate (inpatient and post-discharge) fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) exposure was compared between hospitals with and without fluoroquinolone stewardship. RESULTS: There were 11 748 patients (6820 pneumonia; 4928 positive urine culture) included at 48 hospitals. All hospitals responded to the survey: 29.2% (14/48) reported using pre-prescription approval and/or prospective audit and feedback to target fluoroquinolone prescribing. After adjustment, fluoroquinolone stewardship was associated with fewer patients receiving a fluoroquinolone (37.1% vs 48.2%; P = .01) and fewer fluoroquinolone treatment days per 1000 patients (2282 vs 3096 days/1000 patients; P = .01), driven by lower inpatient prescribing. However, most (66.6%) fluoroquinolone treatment days occurred after discharge, and hospitals with fluoroquinolone stewardship had twice as many new fluoroquinolone starts after discharge as hospitals without (15.6% vs 8.4%; P = .003). CONCLUSIONS: Hospital-based stewardship interventions targeting fluoroquinolone prescribing were associated with less fluoroquinolone prescribing during hospitalization, but not at discharge. To limit aggregate fluoroquinolone exposure, stewardship programs should target both inpatient and discharge prescribing.
引用
- Vaughn VM, Gandhi T, Conlon A, et al. The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study. Clin Infect Dis. 2019. PMID: 30759198. doi:10.1093/cid/ciy1102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。